Advertisement

Cellular and Molecular Life Sciences CMLS

, Volume 62, Issue 19–20, pp 2350–2358 | Cite as

Caffeine intake induces an alteration in human neutrophil A2A adenosine receptors

  • K. Varani
  • F. Portaluppi
  • S. Gessi
  • S. Merighi
  • F. Vincenzi
  • E. Cattabriga
  • A. Dalpiaz
  • F. Bortolotti
  • L. Belardinelli
  • P. A. BoreaEmail author
Research Article

Abstract.

Caffeine is the most widely used drug in the world and acts mainly through antagonism of the effects mediated by the adenosine receptor subtypes A1, A2A, A2B and A3. We determined whether repeated caffeine administration at different doses and for different periods of time (400 or 600 mg/day for 1 week and 400 mg/day for 2 weeks) alters human neutrophil A2A adenosine receptor density and function. Saturation binding assays showed an increase in affinity (KD) and density (Bmax) of A2A adenosine receptors after caffeine intake. These changes were accompanied by increases in cAMP accumulation and decreases in superoxide anion production after stimulation of the A2A receptor subtype using the agonist 5′-N-ethylcarboxamidoadenosine (NECA). Binding and functional changes of A2A receptors returned to baseline after 48 h of caffeine withdrawal. The findings are consistent with a potential anti-inflammatory effect of caffeine mediated by neutrophil A2A receptors.

Key words.

Caffeine adenosine receptors human neutrophils binding assays cyclic AMP superoxide anion production 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Birkhäuser Verlag, Basel 2005

Authors and Affiliations

  • K. Varani
    • 1
  • F. Portaluppi
    • 1
  • S. Gessi
    • 1
  • S. Merighi
    • 1
  • F. Vincenzi
    • 1
  • E. Cattabriga
    • 1
  • A. Dalpiaz
    • 1
  • F. Bortolotti
    • 1
  • L. Belardinelli
    • 2
  • P. A. Borea
    • 1
    Email author
  1. 1.Department of Clinical and Experimental MedicinePharmacology UnitFerraraItaly
  2. 2.Department of MedicineCV Therapeutics Inc.Palo AltoUSA

Personalised recommendations